Drug Trial Radar · NCT04429334
Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support
Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Sep 23, 2020
Primary completion
May 20, 2022
Study completion Jun 22, 2022
Sponsor
- Lead sponsor
- InotremIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo. All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be considered for study participation. The applicable local requirements for informed consent will be followed. Where permissible, an emergency consent procedure will be followed for patients unable to provide consent by themselves. All potential study patients will receive standard of care treatment throughout the study. Patients will receive a continuous intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment with study drug must be initiated as early as possible but no later than 48 hours after the initiation of ventilatory support (Patients will be treated for 5 days or until discharge from critical care, whichever is sooner). Follow-up visits will be performed on days 8 and 14. The end of study visit is at day 28. A further follow up visit will be undertaken on day 60.
Conditions
- COVID19
Interventions
nangibotideDrug
nangibotide 1.0 mg/kg/h
placeboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events until day 28Time frame: 28 days
- Clinical Status (7-point Ordinal Scale) assessed at Day 28Time frame: 28 days
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Clinique universitaire Saint-Luc
Brussels, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
CHU Angers
Angers, France
Centre hospitalier Victor Dupouy
Argenteuil, France
Centre Hospitalier Germont et Gauthier
Béthune, France
CHU Dijon - Bourgogne - Hôpital François Mitterrand
Dijon, France
CHD Site la Roche sur Yon, les Oudairies
La Roche-sur-Yon, France
Centre hospitalier le Manas
Le Mans, France
Centre Hospitalier Universitaire Dupuytren
Limoges, France
Centre hospitalier de Melun
Melun, France
Hôpital Saint Eloi CHU Montpellier
Montpellier, France
Réanimation Médicale, Hôpital Central
Nancy, France
Hôpital Dieu - CHU Nanates
Nantes, France
Hôpital Cochin
Paris, France
Hôpital Civil - Nouvel Hôpital civil
Strasbourg, France
CHRU - Hôpital Bretonneau
Tours, France
Hôpital Franch-Comté Site Trevenans
Trévenans, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.